Legal & General Group
NMRA icon

Legal & General Group’s Neumora Therapeutics NMRA Stock Holding History

Legal & General Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,500
Closed -$10.5K – 3493
2025
Q1 		$10.5K Sell
10,500
-49,342
-82% -$84.5K ﹤0.01% 3161
2024
Q4 		$634K Buy
59,842
+50,289
+526% +$603K ﹤0.01% 2376
2024
Q3 		$126K Buy
9,553
+249
+3% +$2.9K ﹤0.01% 2715
2024
Q2 		$91.4K Buy
9,304
+7,882
+554% +$81.6K ﹤0.01% 2734
2024
Q1 		$19.5K Hold
1,422
– – ﹤0.01% 2971
2023
Q4 		$24.2K Sell
1,422
-8,578
-86% -$105K ﹤0.01% 2955
2023
Q3 		$140K Buy
+10,000
New +$125K ﹤0.01% 2786

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Legal & General Group's NMRA Position: Q2 2025 in Review

Legal & General Group sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 10,500 shares — an estimated $10.5K sold.

Legal & General Group first reported a position in NMRA in Q3 2023 and held it in 7 quarters. The position peaked at $634K in Q4 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • Legal & General Group reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 10,500 Neumora Therapeutics shares in Q2 2025, an estimated $10.5K.
  • Legal & General Group first reported a position in Neumora Therapeutics in Q3 2023 and held it in 7 quarters.
  • Legal & General Group's Neumora Therapeutics position peaked at $634K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.